| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | α5β1integrin |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| Chemical and physical data | |
| Formula | C6434H9942N1706O2040S52 |
| Molar mass | 145501.33 g·mol−1 |
 N Y (what is this?) (verify) | |
Volociximab (also known as M200) is achimericmonoclonal antibody jointly developed byPDL BioPharma andBiogen Idec for treatment of a variety of advancedsolid tumors. It binds to and inhibits the functional activity ofα5β1integrin.[1]
It is thought to reduce metastases. Early results show potential inrenal cell cancers.[citation needed]
 | Thismonoclonal antibody–related article is astub. You can help Wikipedia byadding missing information. |
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byadding missing information. |
